• Администратор

Update on novel P2Y12 inhibitors

Обсуждение медицинских новостей
Ответить
Pyankov Vasily
Сообщения: 4330
Зарегистрирован: Пн ноя 24, 2008 12:59 am
Откуда: Киров

Update on novel P2Y12 inhibitors

Сообщение Pyankov Vasily » Вт фев 23, 2010 8:37 pm

Update on novel P2Y12 inhibitors: Focus on Prasugrel, Ticagrelor, Cangrelor and Elinogrel

Inhibition of the adenosine diphosphate (ADP) P2Y12 receptor plays a key role in antithrombotic therapy as shown by many clinical trials demonstrating the clinical benefit associated with adjunctive clopidogrel therapy in high-risk settings. Despite these clinical benefits, clopidogrel has several limitations such as irreversible effect, variability of antiplatelet response and delayed onset of action. This has led clinical investigations to focus on the development of novel ADP P2Y12 receptor antagonists to overcome these drawbacks. This article summarises current knowledge regarding the ADP P2Y12 receptor antagonists prasugrel, ticagrelor, cangrelor and elinogrel.

http://www.escardio.org/communities/cou ... t=DontMiss

Ответить

Кто сейчас на конференции

Сейчас этот форум просматривают: нет зарегистрированных пользователей и 1 гость